Cita APA

Spreafico, A., Irmisch, A., Bessa, J., Au-Yeung, G., MUÑOZ COUSELO, E., & Bechter, O. (2024). Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: Active drug monitoring to assess the impact of immune response on drug exposure.

Citación estilo Chicago

Spreafico, Anna, Anja Irmisch, Juliana Bessa, George Au-Yeung, EVA MUÑOZ COUSELO, y Oliver Bechter. Phase 1, First-in-human Study of TYRP1-TCB (RO7293583), a Novel TYRP1-targeting CD3 T-cell Engager, in Metastatic Melanoma: Active Drug Monitoring to Assess the Impact of Immune Response On Drug Exposure. 2024.

Cita MLA

Spreafico, Anna, et al. Phase 1, First-in-human Study of TYRP1-TCB (RO7293583), a Novel TYRP1-targeting CD3 T-cell Engager, in Metastatic Melanoma: Active Drug Monitoring to Assess the Impact of Immune Response On Drug Exposure. 2024.